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Chapter 7
The fast and furious — cocaine, amphetamines and harm 
reduction
Jean-Paul Grund, Philip Coffin, Marie Jauffret-Roustide, Minke Dijkstra, Dick de Bruin and 
Peter Blanken
‘The role of the state is not to make people happy but to relieve avoidable suffering.’
(Sir Karl Popper, 1945)
Introduction
Cocaine and amphetamines (‘stimulants’) are distinct central nervous system stimulants with 
similar effects (Pleuvry, 2009; Holman, 1994). Cocaine is a crystalline tropane alkaloid 
extracted from coca leaves. Amphetamines are a subclass of phenylethylamines with 
primarily stimulant effects, including amphetamine, methamphetamine, methcathinone and 
cathinone and referred to as ‘amphetamines’ in this review (Holman, 1994). MDMA 
(3,4-methylenedioxy-N-methamphetamine or ecstasy) is a substituted amphetamine known 
for its entactogenic, psychedelic, and stimulant effects (Morgan, 2000). Stimulants can 
produce increased wakefulness, focus and confidence, elevated mood, feelings of power, 
and decreased fatigue and appetite; stimulants also produce nervousness or anxiety and, 
in some cases, psychosis and suicidal thoughts (Holman, 1994; EMCDDA, 2007f; Hildrey et 
al., 2009; Pates and Riley, 2009). Although there is little evidence that stimulants cause 
physical dependence, tolerance may develop upon repetitive use and withdrawal may 
cause discomfort and depression (EMCDDA, 2007f; Pates and Riley, 2009). Users may 
engage in ‘coke or speed binges’ alternated with periods of withdrawal and abstinence 
(Beek et al., 2001).
Epidemiology of stimulant use in the European Union
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, 2009) 
estimates that at least 3.9 % of the total adult population (15–64 years) in European Union 
(EU) Member States has used cocaine at least once in their lifetime (lifetime prevalence, 
LTP), but variations in prevalence and patterns are found between countries, demographic 
and social groups, and specific settings. Higher levels of cocaine use are found in western 
and southern countries, notably Denmark, Spain, Italy, Ireland and the United Kingdom, 
with relatively low LTP in most other European countries, ranging from 0.1 % to 8.3 % 
(EMCDDA, 2009). Cocaine use is concentrated among young adults (15–34 years), with an 
average LTP of 5.3 %, and more so among young men, with an LTP over 10 % and last 
year prevalence (LYP) over 5 % in Denmark, Spain, and the United Kingdom (EMCDDA, 
2007b). LYP for all EU adults is 1.3 %, ranging from 0 % to 3.1 % by country. LYP among 
young adults is 2.2 %, ranging from 0.1 % to 5.5 %. Last month prevalence (LMP) for all 
adults range from 0 % to 1.1 %, two-thirds of whom are young adults (EMCDDA, 2007f). 
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Cocaine use appears to have increased among young adults since the 1990s and, while 
prevalence is leveling off or decreasing in many countries (EMCDDA, 2007a), Denmark 
and Italy report considerable increases as recently as 2005 and Spain, France, Denmark, 
and the United Kingdom report rapid growth among adults aged 15–24 (EMCDDA, 
2007d). Those countries with data on problem cocaine use include Spain, with 4.5 to 6 
problem cocaine users per 1 000 adults in 2002, Italy with 2.9 to 4.1 per 1 000 adults in 
2005, and England with 5.7 to 6.4 problem crack users per 1 000 adults in 2004/05 
(EMCDDA, 2007c).
Cocaine use is elevated in specific social settings and subpopulations, such as nightlife 
participants with rates from 10 to 60 % (Cohen and Sas, 1993; Cohen and Sas, 1994; 
Decorte, 2001; EMCDDA, 2007d; Nabben et al., 2007; Grund et al., 2007b; Haasen et al., 
2004), sex workers, homeless people, treatment participants and marginalised young adults 
(EMCDDA, 2007d; Haasen et al., 2004). Largely employed, socially integrated users mostly 
sniff cocaine and do so occasionally within rather well-defined leisure settings and periods 
(Prinzleve et al., 2004; Bellis et al., 2003; Cohen and Sas, 1994; Decorte, 2001), with some 
experiencing periods of often short-lived uncontrolled use (Cohen and Sas, 1994; Decorte, 
2001), a finding consistent with laboratory studies in which experienced cocaine users 
regulate their use (Sughondhabirom et al., 2005). Marginalised users, on the other hand, 
very often smoke cocaine-base (crack) or inject cocaine, use more frequently and chaotically, 
and more often use heroin, benzodiazepines or alcohol, while also experiencing a wide 
array of social-economic and medical problems (Prinzleve et al., 2004; Beek, 2001; Hando et 
al., 1997).
LTP of amphetamines among EU adults is 3.3 %, ranging from 0.1 % to 11.9 %, with 0.6 % 
LYP. As with cocaine, more young adults use amphetamines, with 5 % LTP and 1.3 % LYP 
(EMCDDA, 2008). Amphetamines are more common in nightlife, in particular in specific 
dance scenes, such as Hardcore, Tekno or Goa (Nabben et al., 2007; Grund et al., 
2007b). In contrast to cocaine, amphetamine use is higher in northern, central and eastern 
parts of the EU, particularly Sweden and Finland, with rising rates among young adults in 
Austria, Germany, Denmark and southern Italy (Degenhardt et al., 2009). Amphetamine 
injecting is a long-established problem in the Czech Republic and increasing in Slovakia 
and Hungary (where methamphetamine use and injection is common) (EMCDDA, 2008; 
Degenhardt et al., 2009; Griffiths et al., 2008) as well as Estonia and countries across the 
eastern borders, such as Ukraine, Belarus, Russia and Georgia (Degenhardt et al., 2009; 
Griffiths et al., 2008; Grund et al., 2009; Grund and Merkinaite, 2009) Users in former 
Soviet states often produce amphetamine-type stimulants at home (Borodkina et al., 2005; 
Grund, 2001; Heimer et al., 2007), creating an environment where injecting is common 
among recreational users, in contrast to western EU countries where a division between 
integrated (party) and marginalised users of amphetamine seems to exist, similar to that 
between cocaine snorters and smokers or injectors (Grund, 2001; Grund et al., 2009; 
Degenhard et al., 2009).
LTP of ecstasy among EU adults is about 3 %, ranging from 0.3 to 7.3 %, with 0.8 % LYP. 
Among young adults, LTP is 5.6 % and LYP is 1.8 % (EMCDDA, 2008). The geographic 
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diffusion of ecstasy is less clear than that of cocaine and amphetamines, but is associated 
with diffusion of the electronic dance music culture (House or Techno parties, raves, etc.). 
Ecstasy is almost exclusively taken orally, most users are well-integrated and few seek 
treatment barring other drug or alcohol problems (EMCDDA, 2008). Thus, although the 
potential for harm of ecstasy use is not fictional, the reported burden of harm is very low in 
the EU compared to those of cocaine and amphetamines. For this reason this review will 
largely focus on (problem) use of cocaine and amphetamines. Fletcher and colleagues (2010) 
provide an overview of newly emerging harm reduction interventions aimed at users of 
ecstasy, amphetamines and other drugs in recreational settings.
In this review we use the term ‘stimulant(s)’ when discussing cocaine and (meth)amphetamines 
in general terms. We will use ‘cocaine’ when discussing this substance in either its salt or 
base form. ‘Smokable cocaine’ or colloquial terms like ‘crack’ will only be used when 
indicated (as in ‘crack pipes’). Note that the term ‘crack’ is associated with stigma among 
drug users and some prefer saying they smoke ‘free-base’, instead of crack. Likewise, we use 
‘amphetamines’ as a much as possible, when discussing amphetamines in general terms and 
use either ‘amphetamine’, ‘methamphetamine’ or ‘(meth)cathinone’ when referring to those 
specific substances.
Methodology
This review was primarily based on searches in the Medline database for relevant articles. 
Several search terms were used and generally limited papers to those addressing human 
subjects and those published after 1990. The overwhelming majority of articles addressed 
a small number of harms and standardised search terms were unable to identify 
numerous articles known by the authors to be relevant to risk management among 
stimulant users. For example, we searched PubMed on 12 October 2008 for clinical trials, 
metaanalyses, randomised controlled trials, reviews, and practice guidelines involving 
human subjects with the search terms (cocaine or psychostimulants or amphetamine or 
methamphetamine) and (health consequences or overdose or cardiac toxicity or HIV or 
HCV or pregnancy) published after 1990, resulting in 779 papers. After eliminating 
papers that were not relevant (such as animal studies or medical use of stimulants), there 
were 287 articles, of which 49 % referred to pregnancy, 21 % to infectious diseases, 10 % 
to cardiovascular disease, 5 % to neurologic disease, 5 % to other medical problems, 4 % 
to overdose. Several searches were replicated in World of Science and through university 
search engines but with few additional relevant papers identified, nor did including more 
specific search terms related to these topics. A number of articles were identified from 
authors’ previous knowledge and included in the review. With regard to infectious 
disease, stimulant use and harm reduction, 196 articles were identified in English and 
French; after examining these articles and selecting a number of other articles, 91 
references were included. Only a few peer reviewed publications addressed crack use 
and harm reduction, and most of these were grey. Mental health issues were investigated 
in a similar fashion, including a broad search, manual review of the publications, and 
inclusion of outside sources including published papers, reports, organisational materials, 
and other grey publications.
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Adverse (health) consequences associated with use of stimulants
Key findings
Scientific literature is overwhelmingly weighted toward the harms of stimulants, with minimal 
literature on harm reduction interventions. Among the myriad of ill health effects associated with 
stimulants, some are mediated by mode of administration (such as infections, overdose, and 
pulmonary damage) while others are independent thereof (such as neurologic, cardiovascular 
and mental health problems). But the distinction between the two categories of stimulant-related 
harm is subtle and contingent on the broader risk environment. For example:
•   Problem stimulant use is associated with poverty, unemployment, homelessness or unstable 
housing, lower socio-economic status, a variety of other social problems, as well as legal 
problems and incarceration.
•   Adulterants  and  use  of  caustic  chemicals  in  drug  preparation  are  stipulated  by market 
conditions beyond the control of individual users.
•   Traditional harm reduction programmes may fail to reach problem stimulant users due to 
opiate-centred services and social barriers to young or female users.
•   Innovative service development paired with critical evaluation is necessary in translating 
the successes of harm reduction for opiates to stimulants.
•   There  is an  important and unmet need  for services  that enhance  the ability of stimulant 
users to control their intake levels, chaotic behaviour and mental health problems, as well 
as limit pulmonary, cardiovascular and neurologic harms.
•   Stimulant-related harms are aggravated by external  factors, such as selected aspects of 
international drug legislation, policing and public policies in a process of ‘contingent 
causality’.
The risks associated with stimulants include medical harms, such as infectious, cardiovascular, 
and neurologic and psychiatric morbidity, as well as risks to pregnancy, pulmonary and 
renal toxicity, overdose and other less common sequelae. Problem stimulant use is also 
associated with poverty, unemployment, homelessness or unstable housing, lower socio-
economic status, a variety of other social problems, as well as legal problems and 
incarceration. Here we focus primarily on medical health consequences while briefly 
addressing mental health and other problems associated with stimulant use.
Blood-borne viruses
Transmission of blood-borne viruses is consistently associated with stimulant use (Mitchell et al., 
2006), due primarily to high-frequency use and to increased risky sexual behaviors. HIV and 
hepatitis C (HCV) transmission among stimulant injectors has been associated with higher 
injecting frequency (Kral et al., 2001; Gibson et al., 2002) and needle sharing (Rotheram-Borus 
et al., 1999). Frequent cocaine injection is a factor in the failure of selected syringe exchange 
programmes to prevent HIV transmission (Wood et al., 2002). HCV rates are very high, even 
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among recent initiates to cocaine injection (Maher et al., 2007). In central and eastern Europe, 
home-produced stimulants such as methcathinone and cathinone are injected up to 10 times 
daily (Kozlov et al., 2006; Booth et al., 2008; Grund et al., 2009; Chintalova-Dallas et al., 
2009) and are associated with increased sexual activity (Kozlov et al., 2006) as well as sharing 
of equipment in home drug preparation (Grund, 2001; Des Jarlais et al., 2002; Grund and 
Merkinaite, 2009; Balakireva et al., 2006). In comparison to heroin users, stimulant users are 
more likely to have unstable social situations, larger drug-using social networks, riskier injection 
practices (e.g. increased frequency, chaotic drug preparation, injecting in unstable settings) and 
increased sexual activity (De et al., 2007; Elkashef et al., 2008; Grund et al., 1991b; Kozlov et 
al., 2006; Chintalova-Dallas et al., 2009; Booth et al., 2008). HCV is also prevalent among 
non-injection stimulant users, with rates of 2.3–35.3 % among those who sniff or smoke 
stimulants (Scheinmann et al., 2007) and 2.3–81 % among crack smokers (Fischer et al., 2008; 
Jauffret-Roustide et al., 2008a; Tortu et al., 2001); many are unaware that they are infected 
(Roy et al., 2001; Kwiatkowski et al., 2002). Hepatitis B (HBV) infection has also been associated 
with injection and non-injection drug use (NIDU), although the availability of a vaccine has 
greatly reduced infection rates (Kottiri et al., 2005). Stimulant use is associated with infrequent 
condom use (Edlin et al., 1992), amphetamine use preceding sex (Koblin et al., 2006), risk 
behaviours among young gay men (Celentano et al., 2006), and trading sex for drugs or 
money (Serraino et al., 1991; Stevens et al., 1998; Tortu et al., 2000; Tortu et al., 2003).
Cocaine smoking is a distinct risk factor for blood-borne virus transmission (Pechansky et al., 
2006; Haydon and Fischer, 2005; McCoy et al., 2004; Adimora et al., 2003; Edlin et al., 
1994; Chiasson et al., 1991; Haverkos and Steel, 1991), even when adjusted for injection 
behaviour (Wolff et al., 2007; Osher et al., 2003; Nyamathi et al., 2002; Rosenblum et al., 
2001; Roy et al., 2001; Jauffret-Roustide et al., 2006), primarily due to an association with 
risky sexual behaviour (Hagan et al., 2005; McCoy et al., 2004; Edlin et al., 1994; Lejuez et 
al., 2005; Campsmith et al., 2000; Gross et al., 2000; Perlman et al., 1999; Word and 
Bowser, 1997; Centers for Disease Control and Prevention, 1996; Seidman et al., 1994; Edlin 
et al., 1992), with HIV prevalence estimates from 7.5–23.0 % (Jauffret-Roustide et al., 2006; 
McCoy et al., 2004; Edlin et al., 1994; Kral et al., 1998; Gyarmathy et al., 2002). Sex work is 
more frequent among cocaine smokers compared to other drug users (Faruque et al., 1996; 
Edlin et al., 1994; Campsmith et al., 2000; Fischer et al., 2006; Mehrabadi et al., 2008) and 
women cocaine smokers are particularly vulnerable as they are exposed to multiple risks 
associated with both sexual and drug use behaviours, contingent on broader gender 
relations (Jauffret-Roustide et al., 2008b; Shannon et al., 2008; Maranda et al., 2004; 
Cotten-Oldenburg et al., 1999; Heffernan et al., 1996; McCoy and Miles, 1992; Balakireva et 
al., 2006).  While sexual transmission of HIV among cocaine smokers is mainly through 
unprotected intercourse (Haverkos and Steel, 1991), other routes include oral sores and 
cracked lips from hot pipes in the setting of unprotected fellatio (Faruque et al., 1996; Theall 
et al., 2003). Recent studies of cocaine smoking and HCV transmission have noted the 
collective use of glass smoking utensils (‘crack pipes’ or ‘stems’) as a potential risk factor. HCV 
is present in gingival fluid (Suzuki et al., 2005), nasal secretions (McMahon et al., 2004), 
saliva (Hermida et al., 2002), and crack pipes (Fischer et al., 2008), the last of which are 
frequently made of glass, metal or other materials that can get extremely hot, have jagged 
edges, and may break between clenching jaws. Oral sores and burns on lips can result from 
using these pipes (Ward et al., 2000; Faruque et al., 1996; Porter and Bonilla, 1993) and 
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small blood droplets deposit on the stem of the pipe, possibly transmitting HCV to others with 
similar sores (Hagan et al., 2005). One study reported that up to 81 % of all cocaine smokers 
had shared their crack pipes in the previous month (Jauffret-Roustide et al., 2006).
Stimulant use may hasten progression of HIV disease, although data are conflicting. Cocaine 
use has been associated with poor anti-retroviral initiation and adherence (Brewer et al., 
2007), complicated by the interaction of depression, particularly among women (Cook et al., 
2007) whose crack use is strongly associated with poor outcomes of HIV disease (Cook et al., 
2008). While current or past cocaine use is associated with less favorable laboratory 
parameters (T cell and viral load) among patients on HIV treatment, past amphetamine use is 
associated with more favorable parameters (Cofrancesco et al., 2008). Studies of HIV-
positive and HIV-negative men who have sex with men demonstrate no change in T cell 
counts among subjects related to their use of cocaine or amphetamines (Chao et al., 2008), 
and studies among women showed no difference in CD4 count, viral load, or mortality 
(Thorpe et al., 2004). References are available to predict possible interactions of HIV 
medications with illicit drugs (Wynn et al., 2005), but the clinical implication of these 
interactions remains uncertain (Pal and Mitra, 2006). The hypothesis of a direct 
immunomodulatory effect of stimulants that could increase vulnerability to HIV and other 
infections remains unproven (Cabral, 2006).
Other infectious complications
Stimulants have been associated with increased incidence of many sexually transmitted 
diseases including syphilis, gonorrhea, and chancroid (Bauwens et al., 2002; Friedman et al., 
2003; Ross et al., 1999; Ross et al., 2002; Sorvillo et al., 1998; Stoner et al., 2000; Thomas et 
al., 1996; Centers for Disease Control and Prevention, 1991 and 1993; Chirgwin et al., 1991; 
Finelli et al., 1993; Martin and DiCarlo, 1994; Oxman et al., 1996; Shuter et al., 1998; Williams 
and Ekundayo, 2001; Cleghorn et al., 1995), as well as various bacterial infections (Kerr et al., 
2005) and tuberculosis (Malakmadze et al., 2005; McElroy et al., 2003). Cocaine use has been 
independently associated with human papillomavirus infection and progression to cervical 
lesions (Minkoff et al., 2008). Skin and soft tissue infections (SSTIs) affect 10–30 % of injecting 
drug users (IDUs) (Binswanger et al., 2000; Murphy et al., 2001; Ciccarone et al., 2001) and 
are associated with loss of venous access and reliance on intramuscular or subcutaneous 
injection (Ciccarone and Bourgeois, 2003; Lloyd-Smith et al., 2008; Binswanger et al., 2000). 
Injecting crack, vint or boltushka (home-made meth-cathinone) is particularly damaging to veins 
due to the uninformed and unskilled use of chemicals for preparation (Rhodes et al., 2006; 
Chintalova-Dallas et al., 2009). Jeff or boltushka is injected with large-bore needles that rapidly 
damage veins. The United Kingdom has recently seen a rise in groin injection, with an 
estimated 45 % of IDUs in English cities recently injecting into the femoral vein (Maliphant and 
Scott, 2005; Rhodes et al., 2006). Groin injection has been associated with public use of crack 
and speedballs and is now common among new initiates and housed IDUs, not just older and 
homeless users with no other venous access, suggesting a shift from ‘risk boundary’ to 
‘acceptable risk’ (Rhodes et al., 2006; Rhodes et al., 2007). Cocaine injectors, including 
women, those with unstable housing, and those who require help injecting, are independently 
more likely to have SSTIs (Lloyd-Smith et al., 2008).
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Shooting Jeff (homemade methcatinone), Pskov, Russia, 1999
Source: J-P. Grund.
Stimulants are also associated with skin lesions resulting from excessive scratching or picking. 
Most lesions are not due to delusions, apart from ‘Coke Bugs’ or ‘Meth Mites’, which result from 
the sensation that insects are crawling on or under the skin or that the drug is coming out of the 
skin. These are hallucinations from prolonged stimulant use and resulting sleep deprivation 
(Frieden, 2006; Beek et al., 2001; Lee, 2008). Known as delusional parasitosis, this behaviour is 
associated with MRSA, streptococcal, and polymicrobial SSTIs (Hinkle and Nancy, 2000; 
Frieden, 2006; Beek et al., 2001; Cohen et al., 2007). Other self-mutilation behaviours 
observed by outreach workers in Frankfurt include ‘working on wounds with giant knives’ 
(primarily males), cutting (primarily females), cigarette burns and excessive fingernail-biting 
(both sexes) (personal email communication, M. Nickolai, 30 September 2009).
Neurologic effects
Cocaine induces plasticity in the dopaminergic system largely responsible for drug 
craving, yet the principal neurologic effects of cocaine are related to its cardiovascular 
effects: strokes, hemorrhages and blood clots. Persistent vasoconstriction may lead to 
reduced brain perfusion and associated cognitive deficits that may or may not resolve 
with abstinence (Nnadi et al., 2005). Heavy methamphetamine use also induces 
dopaminergic plasticity, as well as reduced dopaminergic activity and neuropsychiatric 
deficits in memory, attention, and executive function (Ferris et al., 2008). Alterations in 
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brain structure and chemistry have been convincingly documented in heavy users of 
methamphetamine although the clinical implications of these data remain uncertain 
(Chang et al., 2007). Numerous studies of long-term prescribed amphetamines have 
failed to demonstrate lasting psychiatric or neurologic deficits, although few are of high 
quality (Vitiello, 2001). In Central and Eastern Europe, chemical residues of home 
stimulant production (including potassium permanganate, gasoline, toluene or 
tetrachlorethylene, sodium hydroxide, or hydrochloric acid) (Grund and Merkinaite, 2009) 
may have toxic effects and local clinicans have reported ‘amphetamine-induced 
movement disorder’ (see e.g. Downes and Whyte, 2005) and declines in cognitive 
function and memory similar to dementia (Volik, 2008; Chintalova-Dallas et al., 2009). 
Pseudoephedrine restrictions in the region may have resulted in use of more hazardous 
precursors such as phenylpropanolamine, associated with hemmorrhagic stroke (Horwitz 
et al., 2000), in production of cathinone (Chintalova-Dallas et al., 2009). In the setting of 
HIV, stimulants have been associated with more rapid progression of cognitive decline 
and recent data suggest that stimulants may contribute to HIV-related neuron cell death, 
particularly within the dopaminergic (Ferris et al., 2008) and hippocampal (Venkatesan et 
al., 2007) systems (Goodkin et al., 1998; Basso and Bornstein, 2000; Nath et al., 2002; 
Cadet and Krasnova, 2007; Ferris et al., 2008).
Cardiovascular effects
Cardiovascular toxicities of cocaine are well-established (Vandhuick et al., 2004). Cocaine 
results in adrenergic activation through effects on norepinephrine and clot formation 
through activation of platelets, resulting in increased cardiac oxygen demand, coronary 
artery spasm, and coronary artery thrombosis. ‘Cocaine chest pain’ is usually not a sign 
of cardiac ischemia, yet cocaine also increases the risk of true myocardial infarction, 
aortic dissection, coronary artery dissection, cardiomyopathy, and sudden cardiac death 
(Steinhauer and Caulfield, 2001; McCord et al., 2008). Injection of any drug is associated 
with endocarditis (Guerot et al., 2002). Cocaine-induced tachycardia and hypertension 
play a role in many of these sequelae (Tuncel et al., 2002), accounted for in part by direct 
reduction in vagal tone (Newlin et al., 2000). Injected cocaine causes a dose-dependent 
prolongation of the QT segment of the cardiac cycle, raising the risk of potentially fatal 
arrhythmias (Haigney et al., 2006), particularly among those with genetic predispositions 
for QT prolongation (Karch, 2005). Overdose of cocaine can result in fatal monomorphic 
ventricular tachycardia by blocking sodium channels (Bauman and DiDomenico, 2002). 
Dilated cardiomyopathy may be related to direct toxicity of cocaine through increased 
programmed death of heart muscle cells (Zhang et al., 1999). Furthermore, prolonged 
cocaine use accelerates atherosclerosis (Kloner et al., 1992) and accumulation of 
metabolites in cardiac tissue may have further detrimental effects (Schindler et al., 1995). 
Clinicians are reluctant to use beta blockers, a key agent in heart disease, to manage 
cocaine-related disease due to fear of producing unopposed activation of other 
adrenergic receptors with cocaine (Afonso et al., 2007). Use of alcohol and cocaine 
together leads to production of cocaethylene, which is believed to increase the cardiotoxic 
effects of both drugs (Kertesz et al., 2007), increases the tachycardia produced by 
cocaine, and may increase the tendency toward violent thoughts and threats (Farre et al., 
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1997; Pennings et al., 2002). Amphetamines produce substantial increases in blood 
pressure and heart rate, more marked when the drugs are injected and somewhat 
buffered among those who also use marijuana (Fleury et al., 2008). Use of ecstasy, 
amphetamine, and cocaine in a club setting did not result in any excess body temperature 
compared to use of alcohol and/or cannabis alone; those drugs did, however, result in a 
relative increase in blood pressure (increase of 40mm Hg systolic) and heart rate (increase 
of 30 beats/minute) (Mas et al., 1999), perpetuating concerns about possible 
cardiovascular toxicities (Cole et al., 2005).
Pulmonary and other health effects
Novel interventions: reinventing the ‘micro’ risk environment
Interventions aimed at reducing harms of cocaine use focus on BBVs and thus on the micro risk 
environment of drug consumption, providing utensils and practical information for safer use.
Crack kit programmes offer kits that generally include a Pyrex tube, plastic tips, filters, 
condoms, lip balm, sterile compresses and chewing gum for salivation (Aidslaw, 2007). An 
evaluation of crack kit distribution in Ottawa (Leonard et al., 2006; Leonard et al., 2007) 
suggested that sharing of crack pipes decreased dramatically, while crack users reduced 
injecting and more often smoked cocaine. The Dutch Mainline Foundation offers cocaine 
information in flyers, on the Internet and on the streets, including a van-based ‘health circuit’ 
for cocaine smokers (Boekhout van Solinge, 2001) to check their lung capacity, blood 
pressure and heart rate. The van is supervised by a trained nurse, providing participatory 
interaction in which pulmonary and mental health harm reduction and self-regulation 
strategies are discussed through motivational interviewing techniques (Wittenberg, 2005). 
Mainline’s website and flyers emphasise practical information for managing health risks and 
controlling cocaine use, including tips for managing coke bugs, the coke shuffle and the urge 
to scratch (e.g. http://www.cocaineinfo.nl/).
Crack kits are controversial and rarely funded. In Canada and some US cities, crack kits are 
distributed with regional funding (Small and Drucker, 2008), but some have closed after local 
opposition (Symington, 2007). At the same time, France is improving access to crack kits 
(Jauffret-Roustide et al., 2008a) with plans for community-based evaluations. Recent 
technological developments such as personal vaporisers, similar to E-cigarettes for tobacco 
smokers, might offer additional opportunities to reduce pulmonary and other bodily harm, as 
vaporisation and filtering could reduce the amount of combustion products inhaled while 
offering an acceptable alternative to crack pipes and perhaps even syringes.
Nonetheless, reactive harm reduction measures focused at the micro risk environment of 
cocaine use do little to mediate the influences in the drug’s macro risk environment, upon 
which risk behaviour and drug related harms are contingent (Rhodes, 2009). This review 
identifies an important need to apply harm reduction thinking in proactive policymaking 
towards changing the ‘contingent causation’ of problem stimulant use with unhealthy drug 
and social policies and those that influence the public domain.
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The most notable pulmonary complication of smoked cocaine, referred to as ‘crack lung’, is 
difficult to differentiate from several other associated and life-threatening restrictive, 
granulomatous, infectious, and hematologic pulmonary diseases and frequently requires 
open-lung biopsy to diagnose (Terra Filho et al., 2004; Wolff and O’Donnell, 2004). The 
vasoconstrictor effect of smoked cocaine can also lead to pulmonary hypertension with 
chronic use (Glauser and Queen, 2007). Asthma exacerbations and eosinophilic pneumonias 
are also described in relation to inhaled stimulants (Mayaud et al., 2001). Intranasal cocaine 
use is clearly associated with septal necrosis and perforation (Glauser and Queen, 2007). 
Use of tobacco is thought to worsen pulmonary outcomes among stimulant smokers or 
injectors (Wolff and O’Donnell, 2004).
Amphetamine use has been associated with dental disease, although there is dispute as to 
the degree of destruction that is related to direct toxicity versus diet and personal hygiene 
(Chi and Milgrom, 2008; Heng et al., 2008). Renal diseases related to stimulants include 
glomerulonephritites, largely believed to be associated with IDU and contaminants, and 
tubulointerstitial processes resulting from vasoconstrictive properties in the setting of pre-
existing mild renal disease (Crowe et al., 2000; Jaffe and Kimmel, 2006). Uncommon 
complications include renal infarction and rhabdomyolisis. Concerns with ecstasy use include 
hyperthermia and rhabdomyolisis with associated renal failure (Hedetoft and Christensen, 
1999). Fear of dehydration has led to consumption of large quantities of water that, in 
individuals without appropriate regulation of antidiuretic hormone, may lead to dilutional 
hyponatremia and, rarely, death (Crowe et al., 2000). Urinary retention due to bladder neck 
closure has also been associated with ecstasy use (Crowe et al., 2000). Gastroschesis, or 
slowed gastric processing of food, has been associated with use of stimulants (Draper et al., 
2008), and cocaine use has been associated with intestinal ischemia, likely due to both 
vasoconstrictor and pro-thrombogenic effects (Glauser and Queen, 2007).
Overdose
Opioids remain the source of most overdose deaths globally, yet in regions such as New York 
City (Coffin et al., 2003) and Sao Paolo, Brazil (Mesquita et al., 2001), the high prevalence of 
cocaine use contributes, often in conjunction with opioids, to the majority of overdose deaths. 
Among cocaine body-packers, overdose can result from the rupture of a container and 
requires immediate laparotomy for chance of survival (Schaper et al., 2007). Extreme 
overdose on stimulants can result in profound hyperthermia, with subsequent risks for 
rhabdomyolisis, seizures, and death (Callaway and Clark, 1994). Overdose on ecstasy 
without concomitant use of other drugs is notably rare and difficult to define, but may be 
related to seritonin syndrome (see ‘Neurologic effects’) (Schifano, 2004). In a survey of all 
amphetamine-related deaths in Belgium, cardiopulmonary arrest and trauma were the most 
common direct causes of death, and drug metabolite levels were notably variable (De Letter 
et al., 2006). Cocaine use is intimately associated with opioid overdose, with combined use 
of the two drugs substantially increasing the risk of both nonfatal and fatal overdose (Ochoa 
et al., 2005; Coffin et al., 2003; Coffin et al., 2007). Furthermore, while overdose on opioids 
is far more likely among IDUs, the rates are closer among injection and non-injection cocaine 
users (Kaye and Darke, 2004).
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Pregnancy and parenting
Stimulant use during pregnancy and parenting has been a major concern, particularly in the 
United States where fears about a future generation of ‘crack babies’ inspired legislation and 
prosecutions against women for stimulant use, marijuana use, or any acts that might be 
considered risky during pregnancy (Harris and Paltrow, 2003). Risk factors for bad outcomes 
among drug-using pregnant women include lack of prenatal care, prior premature delivery, 
and active cigarette smoking (Kuczkowski, 2007; Ness et al., 1999). Cocaine use during 
pregnancy is more likely than opiates, tobacco, and marijuana to be associated with fetal 
growth decrements (Schempf, 2007), and is associated with abruptio placenta and 
premature rupture of membranes; other concerns such as spontaneous abortion, preterm 
labour, behavioural or developmental disabilities, feeding disturbances, or withdrawal 
syndromes were confounded by other variables and often better attributed to maternal 
poverty (Addis et al., 2001). Developmental effects, based on studies utilising vast arrays of 
tools in an effort to elucidate decrements, remain in doubt by some investigators (Frank et al., 
2001), are at most subtle with unclear clinical significance (Lester et al., 2003) and are 
mediated with educational programmes (Schiller and Allen, 2005). Childhood psychiatric 
correlates are mediated by psychosocial factors and diminish as children age (Williams and 
Ross, 2007). There is no risk of direct toxicity to a pregnancy at the time of conception from 
male cocaine use (Klemmt and Scialli, 2005). A thorough 2005 review of amphetamines and 
pregnancy found insufficient evidence to evaluate the developmental toxicity of therapeutic 
amphetamines, with two underpowered cohort studies showing no effect (Golub et al., 
2005). Amphetamines have been associated with a 3.5 fold increased risk of fetal growth 
restriction, while tobacco use had a twofold increased risk (Smith et al., 2006). Early research 
has demonstrated an association between amphetamine-using mothers and poor perceived 
quality of life, increased substance use among family and friends, as well as ongoing legal 
problems (Derauf et al., 2007).
Mental health and social problems
High levels of psychiatric and social comorbidities, in addition to dependence and addiction, 
are found among chronic stimulant users (Hall et al., 1996; Baker et al., 2004; Darke et al., 
2008; Sutcliffe et al., 2009). Chronic amphetamine use is associated with psychosis, usually 
transient during use or withdrawal but occasionally occuring for several years after 
discontinuation (Scott et al., 2007). Pre-existing psychotic symptoms can be greatly exacerbated 
by amphetamine initiation (Hall et al., 1996; Suttcliffe et al., 2009). Stimulant use is also 
associated with suicide, suicidal ideation, depression, post-traumatic stress disorder, and several 
personality disorders (Kertesz et al., 2006; Scott et al., 2007). Methamphetamine use has been 
associated with anti-social personality disorder as well as mania and bipolar mood disorder 
(Chen et al., 2003). Although methamphetamine has been associated with impulsive or violent 
behavior, no causal relationship has ever been established (Scott et al., 2007). Compared to 
cocaine, crack use is associated with higher levels of anxiety, depression paranoia, and 
psychosis, likely due to intensity of use, physical health, and concurrent social situation rather 
than route of administration per se (Haasen, 2005). There is a strong association between 
amphetamine use and attention-deficit hyperactivity disorder (ADHD), which is treated with 
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amphetamine-type medications, leading some investigators to suspect that indviduals with 
ADHD are drawn to amphetamine use (Jaffe et al., 2005; Scott et al., 2007).
Problem use of stimulants is also associated with social and family problems, including poor 
interpersonal relationships, child abuse or neglect, job loss, motor vehicle accidents, trading 
sex for money or drugs, criminal or violent behaviour and homicide (Daley et al., 2002), 
although convincing causal relationships have not been established. Problem stimulant users 
are more likely to be unemployed and experience poor coping skills, limited social support, 
and disorganised lifestyles (Scott et al., 2007), which may play a central role in behavioural 
problems. Furthermore, the criminal and stigmatised nature of stimulant use, while possibly 
deterring wider use, serves as a barrier for problem users to participate in productive society 
(Grabowski et al., 2004).
Harm reduction for stimulant users
Are stimulants too fast and too furious for harm reduction? A relatively new focus for harm 
reduction programmers, stimulants require rethinking many traditional strategies. Here we 
discuss the evidence for, and emerging interventions in, harm reduction for stimulant users. We 
start with a brief review of behavioural and pharmacologic treatment interventions for stimulant 
dependence and then focus on the stimulant-specific harms discussed in the previous section.
Behavioural and pharmacologic interventions for stimulant users
Challenges for harm reduction for stimulant users
Harm reduction for problem stimulant users is both crucial and feasible, but requires 
consideration of the unique characteristics of stimulant use. There are many obstacles, 
including:
•   Frequent cocaine injection is a factor in the failure of selected syringe exchange programmes 
to prevent HIV transmission and in low treatment success and retention.
•   Local studies among IDUs in English cities show show that up to 45 % report recent injecting 
into the femoral vein.
•   Cocaine  smoking  is  a  growing  risk  factor  for  blood-borne  virus  transmission,  due  to 
associations with risky sex and collective use of smoking utensils.
•   Female  users  are  exposed  to  multiple  risks  associated  with  both  sexual  and  drug  use 
behaviours, which are contingent on broader gender relations.
•   Despite  shifts  toward  smoking drugs  in many EU countries, public health efforts  remain 
almost exclusively focused on IDUs.
Independent of mode of administration, stimulant and other drug users must enjoy the 
fundamental human right to health protection, as stipulated by Article 25 of the Universal 
Declaration of Human Rights.
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Generally, the primary goal of treatment is viewed as inducing abstinence and preventing 
relapse (‘cure’). If abstinence is not (yet) feasible, treatment should aim at reducing or at 
least stabilising substance use and its consequences (‘care’). The ultimate stage of 
treatment should be lenitive and aim at alleviating suffering (‘palliation’). At all stages, 
crisis intervention, treatment of intoxication and withdrawal, and improving health, 
psychological and social functioning are self-evident (Health Council of the Netherlands, 
2002).
The first line of treatment for problem stimulant use is outpatient psychosocial intervention 
(American Psychiatric Association, 2007), most notably cognitive behaviour therapy (CBT), 
contingency management (CM) (Dutra et al., 2008), and motivational interviewing (MI) 
(Shearer, 2007; EMCDDA, 2007e). In CM a well-described target behaviour (e.g., 
medication compliance, clinic attendance, stimulant use abstinence, or any other verifiable 
behaviour) is rewarded whenever the behaviour is demonstrated (Dutra et al., 2008). CM 
is most effective when cash (as opposed to vouchers) and higher-value incentives are 
used, and although the effects diminish after the intervention is discontinued, effects of 
incentives have been demonstrated for up to 12 months thereafter (Lussier et al., 2006; 
Prendergast et al., 2006).
There is no proven effective pharmacological treatment for cocaine and stimulant use, in 
spite of the large number of studies on a broad array of pharmaceuticals (for reviews, see: 
De Lima et al., 2002; EMCDDA, 2007e; Pirona and Hedrich, 2009). More recently, the 
Cocaine Rapid Efficacy Screening Trial (CREST) tested 19 medications, of which three 
potentially effective compounds (cabergoline, reserpine and tiagabine) were moved 
forward to be tested in larger, confirmatory trials (Leiderman, 2005; Kampman et al., 
2005). However, in recent larger trials neither tiagabine (Winhusen et al., 2007a) nor 
reserpine (Winhusen et al., 2007b) were effective in reducing cocaine use compared to 
placebo. Another approach is to develop a vaccine to prevent cocaine from crossing the 
blood–brain barrier; the current vaccine needs improvement (Martell et al., 2009) and 
there are many ethical issues to be addressed even once a vaccine has shown to be 
effective (see e.g. Hall and Carter, 2004).
More recently, there is growing interest in shifting the focus from abstinence to ‘substitution 
treatment’, based on the effectiveness of replacement therapy for nicotine and opiate 
dependence (Moeller et al., 2008; Shearer, 2008). The rationale for substitution treatment is 
to replace harmful stimulant drug use ‘with safer, licit pharmaceutical drugs, avoiding 
contaminants and risks associated with hazardous routes of administration, such as injecting 
(blood-borne viral infections, overdose)’ (Shearer, 2008, pp. 302–03). Ultimately, substitution 
treatment should result in a stabilisation of illicit drug use, thereby enabling the stimulant drug 
user to benefit from additional psychosocial interventions. Although the evidence to date for 
substitution treatment of stimulant use is scant (De Lima et al., 2002; Castells et al., 2007), 
dexamphetamine (SR) and modafinil seem promising candidates for further study. Llosa 
(1994) and Hurtado-Gumucio (2000) have also documented in non-controlled studies that 
coca tea, coca leaves and cocaine tablets could be effective in terms of craving, cocaine use 
and social functioning.
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Interventions aimed at reducing adverse (health) consequences associated 
with stimulant use
Blood-borne viruses
Harm reduction for stimulant injectors relies heavily on the evidence for HIV prevention among 
heroin injectors (see e.g. Kimber et al., 2010), but demands consideration of the unique setting 
of stimulant injection. In particular, stimulant injection involves more frequent injection, increased 
sexual risk behaviours, chaotic injecting behaviour, home production, younger ages and more 
frequent treatment utilisation. Stimulant injectors should have easy access to large volumes of 
sterile injection equipment and means of sexual protection, requiring liberal exchange and 
distribution policies, extended opening hours and, where needed, outreach activities in injecting 
and sexual risk environments (Beek et al., 2001; Des Jarlais et al., 2009). Proper injection kits 
should include a range of materials based on local assessment of drug use patterns and the 
social situation of injectors. One-for-one syringe exchange policies, still in place in various 
needle and syringe programmes (NSPs) in the EU and Eastern Europe, should be avoided due 
to the high frequency of stimulant injection.
Harm reduction materials
Collage: Jean-Paul Grund. Source images: Exchange Supplies.
Harm reduction kits for injecting drug users may include needles and syringes, disinfectants, alcohol pads, ascorbic or 
citric acid, filters, single-use cookers, plasters and antibiotic ointments, as well as educational materials. Sometimes other 
specific (e.g. for home preparation in CEE) or generic (such as vitamins or food) items are included as well.
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Longer opening hours for NSPs and liberal exchange policies, political activism and public 
funding are associated with higher coverage of IDU populations and lower rates of risk 
behaviour (Templaski et al., 2008; Bluthenthal et al., 2007a; Bluthenthal et al., 2007b). 
Increased coverage was followed by substantial reductions in HIV prevalence and incidence 
among IDUs in the United States (Santibanez et al., 2006). Exchange Supplies in the United 
Kingdom offers syringes with coloured plungers and ‘syringe-IDs’ (a little colour- and pattern-
marked clip for the back of the plunger), developed to allow stimulant injectors in particular 
to distinguish their personal syringe when injecting collectively (see illustration above).
In response to home-made stimulants, some NSPs in Eastern Europe offer syringes both for 
injecting and for preparing drugs (Grund and Merkinaite, 2009). Harm reduction networks in 
Georgia, Russia and Ukraine are developing interventions and information materials for home-
made stimulant users. Distributing litmus paper to home-made stimulant users to allow 
production of less acidic drugs has been proposed but not yet implemented (Agafonova, 2008).
Traditional harm reduction programmes may fail to reach problem stimulant users due to 
opiate-centered services and social barriers to young or female users (see e.g. Grund and 
Merkinaite, 2009). Outreach, secondary exchange, or peer-driven strategies are needed 
to reach those not attending established service programmes (Needle et al., 2005; Coyle et 
al., 1998; Des Jarlais et al., 2009; Wood et al., 2003; Grund et al., 1992a; Broadhead et 
al., 1998). An unsanctioned peer-based and all-night NSP, located on the street in 
Vancouver’s open drug scene, was able to reach and deliver harm reduction services to 
the city’s most at risk cocaine injectors (Wood et al., 2003). Syringe dispensing machines 
(SDMs) and mobile NSPs provide confidential access to sterile equipment at times and 
places where coverage is poor (Islam and Conigrave, 2007), to younger users (Moatti et 
al., 2001; Obadia et al., 1999) with shorter injection histories than NSP or pharmacy users, 
less drug dependence, less access to established services (Stark et al., 1994; Leicht, 1993), 
less licit income, and lower socioeconomic status (Moatti et al., 2001). Patrons of mobile 
outlets are likely to be younger, indigenous and female, inject more frequently and do so 
more often on the street, be engaged in sex work and not be in drug treatment (Miller et 
al., 2002; Riley et al., 2000; Islam and Conigrave, 2007). SDMs are not advised as stand-
alone interventions as there is little chance for health education, but they can serve as 
strategic adjuncts to conventional NSPs and pharmacy distribution (Islam and Conigrave, 
2007; Agnoletto et al., 1993; Cox et al., 2000).
Despite shifts towards smoking drugs in many EU countries, public health efforts remain 
almost exclusively focused on IDU (Jauffret-Roustide, 2004; Jauffret-Roustide et al., 2008a; 
Haydon and Fischer, 2005; Cheung, 2000). Canada and several US programmes have 
implemented specific programmes for cocaine smokers (Boyd et al., 2008; Leonard et al., 
2006; Leonard et al., 2007), such as the distribution of so-called ‘crack kits’, containing 
supplies to prevent oral or respiratory lesions from smoking (Porter and Bonilla, 1993; 
Malchy et al., 2008; Collins et al., 2005). Studies of the out-of-treatment cocaine and heroin 
users suggest that the principles and evidence base of needle exchange (Wodak and 
Cooney, 2005; Hunt et al., 2003; Hunt et al., 2005; WHO, 2005; WHO et al. and UNODC, 
2004) may apply to crack kits or other drug use utensils as well (Grund, 1991a; Grund, 
1993; Pizzey and Hunt, 2008).
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Although many supervised drug consumption facilities prohibit injected or smoked cocaine 
due to the chaotic and frenetic nature of use, several supervised injection facilities (SIFs) in the 
EU now include rooms for smoking cocaine and other drugs (Hunt, 2006), a trend that may 
extend to Vancouver’s SIF (Shannon et al., 2006). Managing a smoking room has proven 
similar to an injection room; SIFs that do allow cocaine use have not reported major 
problems (Poschadel et al., 2002; Verthein et al., 2001; Zurhold et al., 2001; Zurhold et al., 
2003; Vogt and Zeissler, 2005; Broadhead et al., 2002; Poel, et al., 2003; Hedrich, 2004; 
IWGDCR, 2006). Programmes targeting smokers should emphasise women through gender-
sensitive programmes that have been developed, although few of these have been evaluated 
(Boyd et al., 2008; Wechsberg et al., 2004; Butters and Erickson, 2003). Programming for 
women may work better when biological, behavioural, psychological and social 
characteristics of women are considered and individual and community support measures 
combined (Latka, 2003), supporting increased autonomy of women over their drug use and 
sexuality to minimise exposure to BBVs (Jauffret-Roustide et al., 2008b; Gollub, 2008).
Sexually transmitted diseases, bacterial infections and other complications
Ample supply of injection and sexual protection supplies may also contribute to reducing 
sexually transmitted diseases (STDs) and bacterial infections (Beek et al., 2001; Kerr et al., 
2005). Proper injection techniques, antibacterial creams and ointments and rotation of 
injection sites may help reduce vein loss and effectively treat minor SSTIs (Stern, 1992). Basic 
hygiene (hand washing, short nails) and vein care as well as simple wound care and training 
in safer injection may prevent infections in cocaine injectors (Beek et al., 2001; Kerr et al., 
2005; Rhodes et al., 2007). Wound and abscess services within NSPs may increase patient–
clinician interactions, providing opportunities for referrals to services such as HIV counseling 
and testing, medical care, and drug treatment at an estimated cost of $5 per patient (Grau et 
al., 2002). There is no consensus on whether groin injection should be actively discouraged 
or safer techniques provided (as in the United Kingdom; Maliphant and Scott, 2005; Zador, 
2007; Strang et al., 2008), although investigators agree that transitions to groin injection or 
crack injection should be discouraged (Rhodes et al., 2007).
Neurologic effects
Efforts to reduce the neurologic sequelae of stimulants are primarily related to the use of ‘club 
drugs’. Reducing frequency of use is the most common strategy for reducing the delayed 
‘comedown’ of stimulants, depression, and concerns about neurologic damage (Allott and 
Redman, 2006). ‘Pre-loading’ or ‘post-loading’ with a variety of substances is another 
approach, involving vitamins, foods, antidepressant medications, sleeping tablets, or amino 
acids. While there are no data evaluating the effect of these common methods (Kelly, 2009), 
a combination of amphetamines and most anti-depressant medications poses the risk of a 
life-threatening reaction known as serotonin syndrome (Copeland et al., 2006). A Dutch 
website (http://www.cocaineinfo.nl/) provides neurological explanations for the ‘Coke 
Shuffle’, advising temporary cessation of use, massage, a warm environment or a visit to the 
sauna, as this might help to reduce cramps. Sometimes benzodiazepines are prescribed to 
problem cocaine users, mostly for sleep, but these may also alleviate joint and muscle pains.
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Cardiovascular effects
Routine cardiovascular care, involving diet and exercise, management of high blood pressure 
and cholesterol, as well as reducing other risk factors such as tobacco use, are likely to be 
the most powerful harm reduction strategies, as they are for the general population. 
Reducing dosage and frequency of all stimulant use may reduce cardiovascular toxicities, as 
may reducing concomitant alcohol consumption. Although no controlled studies or specific 
interventions have been conducted, patients maintained on amphetamines (Vitiello, 2008) 
and Andean users of low-potency coca products (Knuepfer, 2003) are believed to be at only 
mild to moderately increased risk of cardiovascular toxicities. As cocaine is directly toxic to 
heart muscle cells while amphetamines exert toxicity primarily through blood pressure 
elevation, reducing or discontinuing use with onset of the cardiovascular disease that comes 
with age is paramount to reducing the harm of these drugs.
Pulmonary and other health effects
While marijuana can be filtered for some reduction in exposure to particulate matter 
(McPartland and Pruitt, 1997), filtering stimulant drugs is less likely to reduce the impact of these 
drugs on pulmonary tissue. Nonetheless, providing filters may reduce oropharyngeal exposure 
to hot embers, thus reducing burns to the mouth and throat. Harm reduction providers in 
Canada, and the United States offer ‘crack kits’ that include Pyrex pipes or rubber mouthpieces 
(Leonard et al., 2006; Leonard et al., 2007; Aidslaw, 2007), which may reduce lacerations to 
the lips. Mainline in Amsterdam offered street cocaine smokers lung, blood and heart 
measurements, safer smoking advice and self-regulation training (Boekhout van Solinge, 2001), 
but roll-out of the methodology in mainstream drug services proved challenging (Bruin et al., 
2008). Other strategies to reduce pulmonary damage could include vaporisation and other 
means to filter out talc and other particles. Sufficient hydration contributes to lip, skin and other 
organ health. The frequency of pneumonia might be mitigated by pneumococcal vaccination 
and tuberculosis prevention, diagnosis and treatment.
The American Dental Association has developed a patient folder on ‘meth mouth,’ that includes 
drug treatment locators, a guide for parents and ‘a calculator to figure out how much it costs to 
support a drug habit’ (American Dental Association, 2005), but provides no advice on oral 
hygiene. Drug users in Amsterdam can get dental care at a special clinic and referrals to 
regular dentists. In Frankfurt in the 1990s, the Integrative Drogenhilfe was reportedly successful 
in finding IDUs dentists in the community using case management and advocacy strategies, as 
part of a ‘Vermittlung in die Normalität’ philosophy towards all their clients’ health, social and 
legal problems (personal communication Marion Nickolai, 15 August 2009).
Overdose
Cocaine overdose is frequently cardiovascular (i.e. heart attack, fatal arrhythmia, or stroke) 
and demands rapid and sophisticated medical management. Concomitant use of opioids, 
alcohol or other depressant drugs is closely associated with cocaine overdose (Kaye and 
Darke, 2004), suggesting that limiting other drug use while using cocaine may reduce the risk 
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of overdose. Cardiopulmonary resuscitation delivered by bystanders has been demonstrated 
to improve outcomes in opioid overdose (Dietze et al., 2002) and may translate to stimulant 
overdoses. Naloxone will not reverse a stimulant overdose, therefore ensuring rapid access to 
nonjudgmental medical care without police intervention is essential to reducing fatalities.
Mental health problems
Many mental health problems associated with stimulant use are dose, frequency and mode of 
administration related, and might be mitigated by specific harm reduction measures. Care 
providers should use a sensitive, respectful approach toward stimulant users, even when chaotic, 
and treat people with signs of drug toxicity, such as cocaine-induced psychosis (Beek et al., 
2001). Brief interventions among recreational amphetamine users should include information 
about potential mental health problems arising from regular use (Baker et al., 2004) and more 
than weekly use or injection should be discouraged (Hall et al., 1996). A randomised-controlled 
trial of Assertive Community Treatment for chronic crack users in Rotterdam found good 
programme compliance and improvements in physical and mental health (Henskens, 2004).
Cessation of cocaine injecting or smoking may be necessary for recovery from cocaine-related 
mental health morbidity (Beek et al., 2001), but self-regulation to control use may also prove 
helpful (Prinzleve et al., 2002; Haasen et al., 2005; Cramer and Schippers, 1994/1996). 
Stimulant users often self-medicate with heroin or other downers to control side-effects of 
anxiety and irritability (Grund, 1993; Decorte, 2001). Acupuncture, while of little use as 
monotherapy, may reduce cocaine craving when provided as an adjunct treatment (Gates et 
al., 2006; Kim et al., 2005) and the service may retain users in care (NTA, 2002). In New York, 
the Lower East Side Harm Reduction Center offers acupuncture, Reiki and other alternative 
treatments to cocaine users (personal communication Raquel Algarin, 23 November 2009).
Other practical suggestions for dealing with the behavioural peculiarities include immediate 
and flexible walk-in services (Haasen et al., 2003, Beek et al., 2001) and offering a calming, 
tranquil environment (Stöver, 2002), similar to ‘chill-out’ rooms at dance parties. 
‘Tagesruheräume’, or daytime rest rooms, for cocaine injectors and crack smokers have been 
established in Frankfurt am Main and integrated within a low-threshold drug help centre, 
which offers counselling, medical and psychiatric care, a consumption room and a shelter in 
Hamburg (Vogt et al., 2000; Stöver, 2001; Verthein et al., 2001). Organisations such as HIT 
in Liverpool, Lifeline in Manchester and Mainline in Amsterdam have developed several 
explicit flyers for cocaine users with tips for managing mental health risks and controlling use 
of cocaine. While a focus of many programmes, approaches developed for stimulant users 
are rarely published in the scientific literature.
Pregnancy and parenting
An ethnographic evaluation of drug-using pregnant women demonstrated numerous self-
employed harm reduction strategies, such as use of less dangerous substances (e.g. 
marijuana), reduced dose and frequency, and improved diet and self-care, as well as less 
helpful strategies like avoiding medical care for fear of stigma or prosecution (Kearney et al., 
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1995; Murphy and Rosenbaum, 1999). Long-term outcome data on early intervention 
programmes for cocaine-exposed children suggest that the impact of poverty far 
overshadows that of cocaine, and that early intervention can improve developmental 
outcomes (Kilbride et al., 2000). Furthermore, among cocaine-exposed children who do not 
receive early interventions, remaining with their birth mothers may result in improved social 
interactions (Kilbride et al., 2006). Substantial harm reduction efforts around stimulants and 
pregnancy in North America have been legal defense and policy reform to reduce the 
criminalisation of women’s behaviour during pregnancy (Lester et al., 2004).
Discussion
Appraisal of the quality of evidence reviewed and limitations of the study
Research has established the rationale for many harm reduction interventions for stimulant 
users (Wodak and Cooney, 2005; Farrell et al., 2005; Hunt et al., 2003; Hunt et al., 2005; 
WHO et al., 2004). Nonetheless, scientific literature is overwhelmingly weighted toward 
the harms of stimulants, with minimal literature on harm reduction interventions. 
Investigations frequently consider stimulants users a subset, rather than the target 
population of a study. Several interventions for stimulant users, such as providing materials 
for safer crack smoking or safer groin injection training, remain controversial or illegal and 
thus systematic evaluations are lacking. Funding mechanisms for evaluating new 
interventions are also limited, partly due to the reliance of most investigators on HIV 
funding streams.
Potential harms addressed by harm reduction interventions
The effectiveness of pharmacological and psychosocial interventions for stimulant users is 
limited (De Lima et al., 2002; EMCDDA, 2007e; Pirona and Hedrich, 2009), thus 
interventions to stabilise and minimise the negative consequences of ongoing stimulant use 
are of paramount importance. The evidence suggests that there are no fundamental 
challenges in adjusting regular harm reduction interventions, such as NSPs and SIFs, towards 
BBV prevention among problem stimulant users. However, a wide range of health and social 
problems associated with stimulant use are largely unaddressed by current services (e.g. 
specific harm reduction approaches to SSTIs have been developed but are not widely 
implemented (Grau et al., 2002; Kerr et al., 2005)).
Prevention of SSTIs, overdose or pulmonary, neurologic, or cardiovascular damage is a 
relatively new focus in harm reduction and there is much ground to be gained in prevention 
and early treatment of these conditions. ‘Crack kits’ may prove useful in preventing certain 
infections. Widely available SSTI, and cardiac primary care services, may lessen the burden 
of disease. The rapidly expanding literature on overdose prevention programming (Sporer 
and Kral, 2007; Maxwell et al., 2006; Coffin et al., 2007; Coffin, 2008) suggests a need to 
extend the harm reduction philosophy even further. Innovative service development paired 
with critical evaluation is necessary in translating the successes of harm reduction towards 
heroin to stimulant use.
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Community-based research, programme evaluations and best practice examples underscore 
the need for services that enhance the ability of stimulant users to manage their intake levels, 
chaotic behaviour and mental health problems. Several harm reduction programmes 
informally aid stimulant users in money management, at times even holding clients’ benefit 
cheques until after a binge. At hundreds, if not thousands, of blogs and Internet discussion 
lists, users discuss stimulant and other drug use openly and in detail, including many of the 
harms discussed in this review, dietary advice and ‘street pharmacology’ approaches to self-
regulation (e.g. ‘Harm Reduction for Stimulants’, http://www.drugs-forum.com/forum/
archive/index.php/t-24802.html).
Rhodes and colleagues reported what could be termed an epidemic of groin injecting. 
When groin injection becomes an ‘acceptable risk’ (Rhodes et al., 2006), one wonders 
what other risks have pushed the normalisation of this hazardous behaviour down the 
injector’s ‘hierarchy of risk’ (Connors, 1992). Rhodes and colleagues not only point 
towards increasing crack/speedball injection in their explanation, they also emphasise the 
changing ‘risk environment’ of drug injecting (Rhodes, 2002). Groin injection is reportedly 
viewed as ‘reliable, speedy, and discreet’. As one of their respondents explained, ‘you can 
do it under a camera’ (Rhodes et al., 2006). The omnipresence of camera and human 
surveillance, zero tolerance towards deviance in the public space and the resulting lack of 
spaces where homeless IDUs could withdraw to inject in British (and other) cities can thus 
be seen to engender a risk environment in which ‘macro risk factors’ synergise the risks of 
crack injection towards aggravating injecting-related harm (Rhodes, 2002; Rhodes et al., 
2006; Rhodes, 2009). Such environmental factors are mostly beyond the scope of harm 
reduction interventions, which focus primarily on the substance and its users. Nonetheless, 
in the early 1980s, when cocaine landed in the urban heroin scenes of the Netherlands 
and injecting was still the dominant mode of drug administration, IDUs did not turn ‘en 
masse’ towards groin injecting (Grund et al., 1991b). Instead, smoking cocaine at ‘house 
addresses’ became the norm (Grund et al., 1991a; Grund and Blanken, 1993; Blanken et 
al., 1997).
The harms associated with problem stimulant use interact at multiple levels in the risk 
environment (Rhodes, 2002; Zinberg, 1984). Not only can specific harms influence one 
another, but they are also aggravated by external factors, such as international drug 
legislation, policing and other public policies in a process of ‘contingent causality’ (Rhodes, 
2009). Developing proper and timely responses to such policy-related harms is a crucial 
challenge to harm reduction. Not because the proper harm reduction tools are absent or 
cannot be imagined, but because the larger risk environment might make such efforts null 
and void (Grund et al., 1992b; Rhodes et al., 2006; Gostin, 1998). Policymakers should 
therefore find ways to reduce the harms from counter-effective drug policies, harsh social 
policies and policies affecting our public space and private behaviours, and strengthen the 
ability of drug consumers and society to learn from past experience.
History is full of examples of the acculturation of ‘new’ psychoactive drugs across various 
cultures. As part of the mainstream social fabric, most drinking is restrained by explicit and 
implicit social rules passed from generation to generation. Unfortunately, the collective 
knowledge on cocaine and amphetamines is accumulated through peer-based learning and 
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not necessarily passed on automatically to new generations of users. The potential to respond 
in a rational and healthy fashion to ‘new’ illicit drugs is — among users and policymakers 
alike — hampered by what Lloyd Johnston termed ‘generational forgetting’ (Johnston et al., 
2004). Yet, this learning is crucial to peacefully controlling problem drug use, a role recently 
adopted by harm reduction providers in many countries.
Implications for future intervention development, research and policy
There is a strong base of needle exchange programming in many, but not all, EU Member 
States, but their coverage of the IDU population may vary and stimulant users are poorly 
reached. Developing sufficient coverage for NSP and other interventions is a clear but 
complex issue (Des Jarlais et al., 2009) (see Kimber et al., 2010). Therefore, internal and 
external regulatory barriers, such as one-for-one exchange policies and laws that impede 
harm reduction programmes from distributing other safer use supplies (e.g. crack pipes and 
smoking foil) should be reconsidered. While returning used injecting equipment should be 
encouraged, the strict combination of distribution and collection is an unsavoury choice as it 
hinders access to ample quantities of injecting equipment at places and times when these are 
most needed. Therefore, independent distribution and collection schemes should be 
developed (Des Jarlais et al., 2009; Wood et al., 2003; Grund et al., 1992a).
The volume of injection equipment or condoms provided to clients should be determined 
based on a thorough assessment of clients’ needs and network characteristics (Braine et al., 
2008; Friedman et al., 2007; Rothenberg, 2007). All this requires a paradigm shift in service 
provision — from institutional provider–client relationships to facilitation of peer prevention in 
user networks (Broadhead et al., 1998) through peer-based outreach and secondary 
exchange. Syringe vending machines and mobile programmes can be useful adjuncts to 
‘reaching the unreached’ but should be firmly based in flexible, attractive and human-
delivered services.
Safer injecting and smoking education and interventions supporting transition to less 
harmful routes of drug administration, as well as overdose prevention and medical care of 
vein, skin and other infections should become standard features of SIFs and NSPs, and 
moved into the mainstream of harm reduction. NSPs and SIFs should not only create a 
healthy atmosphere, but also a setting that allows for the pleasurable effects of stimulants 
while minimising negative experiences, possibly by emphasising more controlled and less 
frenetic use. Relaxation techniques and alternative therapies may help stimulant users to 
ameliorate some of the mental health effects of heavy or frequent stimulant use, as well as 
physical complaints such as musculoskeletal pain. Offering sleep and day rest facilities 
may help to reduce sleep deprivation, which may alleviate the mental health strain of 
stimulant use. Involving participants in service provision and other activities may further 
help reduce the frequency and amounts of stimulant use, potentially leading to 
improvements in mental health and social functioning. Collaborations between various 
medical specialties, drug users, service providers and researchers in designing harm 
reduction strategies towards the pulmonary, cardiovascular and neurologic effects of 
stimulant use are equally important.
Harm reduction: evidence, impacts and challenges
212
The reviewed studies suggest that problem stimulant use requires innovative, integrated 
and multidisciplinary medical and social services, but also drug and social policies that 
do not exacerbate the already considerable potential for harm of stimulants. The recent 
attention being paid to the unintended consequences of drug policy at UNODC is 
encouraging, but needs to be translated into effective action. At present, international 
drug and other public policies emphasise maximising harm to reduce casual drug use. 
Stimulant and other drug users must enjoy the fundamental human right to health 
protection, as stipulated by Article 25 of the Universal Declaration of Human Rights 
(General Assembly of the United Nations, 1948). In 1945, at the brink of war and peace, 
Sir Karl Popper published his influential The open society and its enemies, in which he 
wrote ‘The role of the state is not to make people happy but to relieve avoidable 
suffering.’ For the state and its agents to live up to these calls is amongst the principal 
challenges of harm reduction.
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